Thank you for standing by. I would like to welcome you to the Intensity Therapeutics Inc. 2025 Annual Meeting. I would now like to turn the conference over to Mr. Bender, Chief Executive Officer. Please go ahead.
Thank you, Bella. Good morning. Welcome to the 2025 Annual Meeting of Stockholders of Intensity Therapeutics Inc. I'm Lew Bender, President, Chief Executive Officer, and Chairman of the company. It is my pleasure to welcome all of you. It is 10:30 A.M. Eastern Time, and in accordance with the notice of the meeting, I call to order the 2025 Annual Meeting of Stockholders of Intensity Therapeutics. We have chosen to have this meeting virtually in order to improve our stockholders' access to the meeting. It is our intention to conduct this meeting in accordance with the agenda. The agenda is currently available for review in the meeting materials section of the meeting website. You will note that under item 10 of the agenda, an opportunity is provided at the end of the meeting for general questions and discussions.
Please adhere to the rules for conduct attached to your agenda in asking questions at that time. Before proceeding to the business of the meeting, I would like to introduce some people who are with us today on the webcast. First, I would like to introduce our present directors. In addition to myself, we are welcomed by Dr. Emer Leahy, Dr. Mark A. Goldberg, Daniel Donovan, and Thomas Duven. Dr. Mark A. Goldberg is a candidate for reelection at today's meeting. Also present today are Joseph Calamo, the company's Chief Financial Officer, and John Wasilowski, the company's Principal Accounting Officer and Controller, as well as Jeff Schultz and Hannah Zelzer from Mintz, the company's attorneys. James R. Alvin of American Election Services LLC is here as the Inspector of Elections for this meeting.
If questions arise during the discussion period that these individuals should appropriately address, they will be glad to respond. Joseph Calamo will serve as Secretary of the meeting. This meeting is held pursuant to a printed notice mailed on or about June 2, 2025 to each stockholder of record as of May 28, 2025. The count of shares present immediately prior to the commencement of the meeting indicated that 10,989,589 shares of the company's voting capital stock were present in person or by proxy. This is 59.73% of the outstanding voting stock of the company. I hereby declare a quorum present at the meeting. On behalf of the Board of Directors, I would like to express my appreciation to all stockholders who returned their proxies.
I would also like to point out that most of you who returned proxies authorized the persons named in the proxy to vote for the election of management's nominees for Director. Those of you who would like to vote today may do so by clicking on the button on your screen entitled Vote Here. The first matter to be acted upon by the stockholders is the election of one Director to serve until the annual meeting to be held in 2028 and until the successor has been elected and qualified. I have just introduced the nominee, and additional information about the nominee is in the proxy statement. I hereby declare Dr. Mark A. Goldberg duly nominated. The company has not received timely notice of any other nominations, therefore, I declare the nominations closed. If you have questions regarding this proposal, please submit questions regarding this proposal now.
The last matter submitted to the stockholders for action is the ratification of the appointment by the Board of Directors of EisnerAmper LLP as Auditors of Intensity Therapeutics Inc. If you have questions regarding this proposal, please submit questions regarding this proposal now. The stockholders who are voting at the meeting on these proposals should now vote. The polls will be open for a minute or two to vote on all proposals. After voting has been completed, votes will be counted. Please vote on each proposal using the links provided in the webcast. I will read during this interim voting period the rules of conduct. If you wish to address the meeting, please type your question into the box labeled Ask a Question and click Submit. Questions or remarks must be relevant to the meeting, pertinent to matters properly before the meeting, and briefly stated.
The meeting is not to be used as a forum to present general economic, political, or other views that are not directly related to the business of Intensity Therapeutics Inc. If any stockholders have any special questions not relating to the meeting or not of concern to the stockholders generally, one of the officers of the company will discuss the matter with them after the meeting or at some other mutually convenient time. At this time, I hereby declare the polls closed for all proposals. We will prepare preliminary results of the voting at this time. We have completed a preliminary count of the ballots, and the majority of the votes have been voted for the election of Dr. Mark A. Goldberg for term expiring in 2028.
Finally, in connection with the ratification of the appointment of EisnerAmper LLP to audit the financial statements of the company and its subsidiaries for the fiscal year 2025, 10,922,860 shares, being more than a majority of the voting stock of the company, have been voted in favor. 17,438 shares have been voted against, and 49,291 shares have abstained. I hereby declare that Dr. Mark A. Goldberg has been duly elected and that the appointment of EisnerAmper LLP to audit the financial statements of the company for fiscal year 2025 has been duly ratified. After the final tabulation has been completed, it should be placed with the minutes of this meeting. The final results will be disclosed in a current report on Form 8-K to be filed within four business days of this meeting. This concludes the formal portion of our meeting.
I would again like to express my sincere appreciation to the stockholders who attended this meeting and voted, as well as those who submitted their proxies. The meeting is now formally adjourned. However, we are available to discuss questions which any of you may have. Please be advised that my remarks and management's response to questions at the end of this meeting will contain some forward-looking statements. In compliance with the Private Securities Litigation Reform Act of 1995, I am advised to point out that actual results may differ significantly from results discussed in the forward-looking statements. Factors that might cause such a difference include those set forth from time to time in the company's SEC filings, including its annual report on Form 10-K for the year ended 2024. We have now come to the part of the agenda providing for general questions and discussions. Any questions?
We have not received any questions, and so the Q&A portion of the meeting is now closed. Thank you again to our stockholders.
That concludes today's meeting. Thank you all for joining. You may now disconnect. Everyone, have a great day.